МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЕ МАРКЕРЫ В РАЗВИТИИ И ПРОГНОЗИРОВАНИИ ОСЛОЖНЕНИЙ ПРИ СИНДРОМЕ ШЕРЕШЕВСКОГО-ТЕРНЕРА
Ключевые слова:
хромосома, низкорослость, порокиАннотация
Синдром Шерешевского-Тернера — хромосомное заболевание, возникающее в результате полной или частичной потери одной из Х-хромосом у фенотипически женщин. Клинические особенности зависят от кариотипа и обычно включают низкорослость, гипергонадотропный гипогонадизм вследствие дисгенезии яичников, пороки сердца и нейрокогнитивные нарушения.
Библиографические ссылки
Al Alwan I.M, Amir I. et al. Turner Syndrome Genotype and phenotype and their effect on presenting features and timing of Diagnosis. Int J Health Sci (Qassim). 2014; 8(2):195-202. doi: 10.12816/0006086.
Aversa T., Messina M., Mazzanti L. et al. The association with Turner syndrome significantly affects the course of Hashimoto’s thyroiditis in children, irrespective of karyotype. Endocrine. 2015; 50: 777–782. doi: 10.1007/s12020-014-0513-6.
Aversa T., Salerno M., Radetti G. et al. Peculiarities of presentation and evolution over time of Hashimoto’s thyroiditis in children and adolescents with Down’s syndrome. Hormones (Athens). 2015а; 14: 410–416. doi: 10.14310/horm.2002.1574.
Baguet J. Douchin S. Pierre H. et al. Structural and functional abnormalities of large arteries in Turner syndrome. Heart. 2005; 91: 1442–1446.
Bakalov V., Axelrod L., Baron J. et al. Selective reduction in cortical bone mineral density in Turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab. 2003; 88: 5717–5722. doi: 10.1210/jc.2003-030913.
Bakalov V., Bondy C. Fracture risk and bone mineral density in Turner syndrome. Rev Endocr Metab Disord. 2008; 9: 145–151. doi: 10.1007/s11154-008-9076-2.
Bianco B., Verreschi I., Oliveira K. et al. Analysis of vitamin D receptor gene (VDR) polymorphisms in Turner syndrome patients. Gynecol Endocrinol. 2012; 28(4): 326-329. doi: 10.3109/09513590.2011.631630.
Bondy C. Congenital cardiovascular disease in Turner syndrome. Congenit Heart Dis. 2008; 3(1): 2-15. doi: 10.1111/j.1747-0803.2007.00163.x.
Calcaterra V., Gamba G., Montani N. et al. Thrombophilic screening in Turner syndrome. J Endocrinol Invest. 2011 Oct; 34((9)): 676–679.
Calcaterra V., Larizza D., De Giuseppe R. et al. Diet and Lifestyle Role in Homocysteine Metabolism in Turner Syndrome. Med Princ Pract. 2019; 28(1): 48-55. doi: 10.1159/000494138.
Chiarito M., Brunetti G., D’Amato G., Faienza M. Monitoring and maintaining bone health in patients with Turner syndrome. Expert Rev Endocrinol Metab. 2020; 15: 431–438. doi: 10.1080/17446651.2020.1834846.
Chiarito M., Piacente L., Chaoul N. et al. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome. J Endocrinol Invest. 2022; 45(6): 1255-1263. doi: 10.1007/s40618-022-01760-3.
Dudmam N. An alternative view of homocysteine. Lancet. 1999; 8: 65–68.
Faienza M., Ventura A., Colucci S. et al. Bone fragility in Turner syndrome: mechanisms and prevention strategies. Front Endocrinol. 2016; 7: 34. doi: 10.3389/fendo.2016.00034.
Gasperini B., Visconti V., Ciccacci C. et al. Role of the Vitamin D Receptor (VDR) in the Pathogenesis of Osteoporosis: A Genetic, Epigenetic and Molecular Pilot Study. Genes (Basel). 2023; 14(3): 542. doi: 10.3390/genes14030542.
Goyette P., Summer J., Milos R. et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994; 7: 195–200.
Holroyd C., Davies J., Taylor P. et al. Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. Osteoporos Int. 2010; 21: 2093–2099. doi: 10.1007/s00198-010-1170-0.
Kaldmäe M., Zilmer M. Viigimaa M, et al. Cardiovascular disease risk factors in homeless people. Ups J Med Sci. 2011; 116: 200–2007.
Kim H., Gottliebson W., Hor K. et al. Cardiovascular anomalies in Turner syndrome: spectrum, prevalence, and cardiac MRI findings in a pediatric and young adult population. AJR Am J Roentgenol. 2011; 196: 454–460.
Lloyd-Jones D., Leip E. Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 1996; 113: 791–798.
Lopez L., Arheart K., Colan S. et al. Turner syndrome is an independent risk factor for aortic dilation in the young. Pediatrics. 2008; 121: 1622–1627.
Malinowska J., Kolodziejczyk J., Olas B. The disturbance of hemostasis induced by hyperhomocysteinemia; the role of antioxidants. Acta Biochim Pol. 2012; 59((2)): 185–194.
Mavinkurve M., O'Gorman C. Cardiometabolic and vascular risks in young and adolescent girls with Turner syndrome. BBA Clin. 2015; 3: 304–309.
McCully K. Chemical pathology of homocysteine. I. Atherogenesis. Ann Clin Lab Sci. 1993; 23((6)): 477–493.
McCully K. Chemical pathology of homocysteine. III. Cellular function and aging. Ann Clin Lab Sci. 1994; 24((2)): 134–152.
McCully K. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann Clin Lab Sci. 2009; 39((3)): 219–232.
Nahar A., Sabo C., Chitlur M. et al. Plasma homocysteine levels, methylene tetrahydrofolate reductase polymorphisms, and the risk of thromboembolism in children. J Pediatr Hematol Oncol. 2011; 33((5)): 330–333.
Obersby D., Chappell D., Dunnett A., Tsiami A. Plasma total homocysteine status of vegetarians compared with omnivores: a systematic review and meta-analysis. Br J Nutr. 2013; 109((5)): 785–794.
Oliveira K., Verreschi I., Sugawara E. et al. C677T and A1298C polymorphisms of MTHFR gene and their relation to homocysteine levels in Turner syndrome. Genet Test Mol Biomarkers. 2012 May; 16((5)): 396–400.
Oliveira R., Verreschi I., Lipay M. et al. Y chromosome in Turner syndrome: review of the literature. Sao Paulo Med J. 2009; 127: 373–378
Peralta López M., Centeno V., Miras M. et al. Association of vitamin D receptor gene Cdx2 polymorphism with bone markers in Turner syndrome patients. J Pediatr Endocrinol Metab. 2012; 25(7-8): 669-671. doi: 10.1515/jpem-2012-0098.
Peralta López M., Miras M., Silvano L. et al. Vitamin D receptor genotypes are associated with bone mass in patients with Turner syndrome. J Pediatr Endocrinol Metab. 2011 ;24(5-6): 307-312. doi: 10.1515/jpem.2011.047.
Refsum H., Smith A., Ueland P. et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004; 50((1)): 3–32.
Santos L., Laranjeira R., Borborema M. et al. Vitamin D receptor (VDR) gene polymorphisms and expression profile influence upon the immunological imbalance in Turner syndrome. J Endocrinol Invest. 2020; 43(4): 505-513. doi: 10.1007/s40618-019-01135-1.
Steed M. & Tyagi S. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal. 2011; 15: 1927–1943.
Viuff M., Skakkebæk A., Nielsen M. et al. Epigenetics and genomics in Turner syndrome. Am J Med Genet. 2019; 181: 125–132. doi: 10.1002/ajmg.c.31683.
Yang J., Hu X., Zhang Q. et al. Homocysteine level and risk of fracture: A meta-analysis and systematic review. Bone. 2012; 51((3)): 376–382.
Yang R., Pu D., Tan R., Wu J. Association of methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms (C677T and A1298C) with thyroid dysfunction: A meta-analysis and trial sequential analysis. Arch Endocrinol Metab. 2022; 66(4): 551-581. doi: 10.20945/2359-3997000000471.
